Improving Outcomes in Rheumatoid ArthritisTreating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
McInnes IB, et al. Ann Rheum Dis. 2015;74(4):694-702.
Kim GW, et al. Arch Pharm Res. 2015;38(5):575-584.
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab
Tanaka Y, Martin Mola E. Ann Rheum Dis. 2014;73(9):1595-1597.
Anderson JK, et al. Arthritis Care Res (Hoboken). 2011;63(suppl 11):S14-S36.
McInnes IB, Schett G. N Engl J Med. 2011;365(23):2205-2219.
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study
Genovese MC, et al. Arthritis Rheumatol. 2015;67(6):1424-1437.
Dennis G Jr, et al. Arthritis Res Ther. 2014;16(2):R90.
Burmester GR, et al. Ann Rheum Dis. 2015.
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year
Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Gabay C, et al. Lancet. 2013;381(9877):1541-1550.
IL-6 in Rheumatoid Arthritis
From Pathophysiology to Individualized Therapy
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates & Discussions on the Evolving Role of JAK Inhibitors
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow